The emergency department as a setting‐specific opportunity for population‐based hepatitis C screening: An economic evaluation

Abstract

Background and Aims:The World Health Organization's hepatitis C virus (HCV) elimination strategy recognizes the need for interventions that identify populations most affected by infection. The emergency department (ED) has been suggested as a setting for HCV screening. The study objective was to explore the health and economic impact of HCV screening in the ED setting. Methods:We used a microsimulation model to conduct a cost-utility analysis evaluating two ED setting-specific strategies: no screening, and screening and subsequent treatment. Strategies were examined for two populations: (a) the general ED patient population; and (b) ED patients born between 1945 and 1975. The analysis was conducted from a healthcare payer perspective over a lifetime time horizon. A reference and high ED HCV seroprevalence measure were examined in the Canadian healthcare setting.US costs of chronic infection were used for a scenario analysis of screening in the US healthcare setting. Results: For birth cohort screening, in comparison to no screening, one liver-related death was averted for every 760 and 123 persons screened for the reference and high seroprevalence measures. For general population screening, one liver-related death was averted for every 831 and 147 persons screened for the reference and high seroprevalence measures. In comparison to no screening, birth cohort screening was cost-effective at CAN$25,584/quality-adjusted life year (QALY) and US$42,615/QALY. General population screening was cost-effective at CAN$19,733/QALY and US$32,187/QALY. Conclusions: ED screening may represent a cost-effective component of populationbased strategies to eliminate HCV. Further studies are warranted to explore the feasibility and acceptability of this approach. K E Y W O R D S cost-utility analysis, economic evaluation, emergency department, hepatitis C, screening | 1283 MENDLOWITZ ET aL.

Melatonin potentials against viral infections including COVID-19: Current evidence and new findings

“…According to recent reports, viral hepatitis will be eliminated until 2030. In this regard, the number of infected individuals and associated mortality should be reduced by 90 % and 65 %, respectively ( Mendlowitz et al, 2020 ). Rabbit hemorrhagic disease (RHD) is a greatly lethal viral infection in rabbits characterized by severe necrotizing hepatitis and disseminated intravascular coagulation in the liver, kidney and spleen( Beller et al, 1969 ).…”

Universal Screening for Hepatitis C Virus in the ED Using a Best Practice Advisory

“… 10 With HCV testing becoming more affordable and curative therapy now available, the benefit of early detection with linkage-to-treatment in individuals with chronic infection likely outweighs the cost of increased testing. 21 …”

“…10 With HCV testing becoming more affordable and curative therapy now available, the benefit of early detection with linkage-to-treatment in individuals with chronic infection likely outweighs the cost of increased testing. 21 To assess the impact of provider bias on screening practices we compared demographic proportions of screened individuals before and after the implementation of the BPA. In the pre-BPA period, individuals tested were more likely to be male (60%).…”

Correlation of SARS-CoV-2 Infection with Hepatitis and Liver Disorders

“…World Health Organization (WHO) aims to eliminate viral hepatitis until 2030, which means the number of newly infected subjects, and related mortality should be reduced by 90% and 65%, respectively. This program covers various approaches, including diagnosis, treatment, vaccination against hepatitis B virus (HBV), preventing transmission from mother to child, and blood safety [11,12]. Although scientists have recently focused on developing effective drugs and vaccines for COVID-19, other diseases and pathogens should be considered, as well [13].…”